NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.
Stock data | 2024 | Change |
---|---|---|
Price | $2.34 | N/A |
Market Cap | $17.79M | N/A |
Shares Outstanding | 7.61M | N/A |
Employees | 0 | N/A |